$3.75
Affimed is a biotechnology business based in the US. Affimed shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed employs 76 staff and has a trailing 12-month revenue of around $9.3 million.
Our top picks for where to buy Affimed stock
How to buy Affimed stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AFMD. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Affimed stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Affimed stock price (NASDAQ: AFMD)
Use our graph to track the performance of AFMD stocks over time.Affimed shares at a glance
Latest market close | $3.95 |
---|---|
52-week range | $2.24 - $8.95 |
50-day moving average | $4.83 |
200-day moving average | $5.24 |
Wall St. target price | $24.12 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-6.92 |
Is it a good time to buy Affimed stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Affimed price performance over time
Historical closes compared with the close of $3.95 from 2024-09-03
1 week (2024-08-29) | -10.63% |
---|---|
1 month (2024-08-05) | -9.40% |
3 months (2024-06-05) | -40.15% |
6 months (2024-03-05) | 490.43% |
1 year (2023-09-05) | 634.20% |
---|---|
2 years (2022-09-02) | 50.76% |
3 years (2021-09-03) | 6.69 |
5 years (2019-09-05) | 34.81% |
Affimed financials
Revenue TTM | $9.3 million |
---|---|
Gross profit TTM | $42.9 million |
Return on assets TTM | -46.12% |
Return on equity TTM | -112.37% |
Profit margin | 0% |
Book value | $2.67 |
Market Capitalization | $64.4 million |
TTM: trailing 12 months
Affimed share dividends
We're not expecting Affimed to pay a dividend over the next 12 months.
Have Affimed's shares ever split?
Affimed's shares were split on a 1:10 basis on 10 March 2024. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Affimed shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Affimed shares which in turn could have impacted Affimed's share price.
Affimed share price volatility
Over the last 12 months, Affimed's shares have ranged in value from as little as $2.235 up to $8.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed's is 2.11. This would suggest that Affimed's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Affimed overview
Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
Frequently asked questions
nullWhat percentage of Affimed is owned by insiders or institutions?
Currently 6.007% of Affimed shares are held by insiders and 35.397% by institutions. How many people work for Affimed?
Latest data suggests 76 work at Affimed. When does the fiscal year end for Affimed?
Affimed's fiscal year ends in December. Where is Affimed based?
Affimed's address is: Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165 What is Affimed's ISIN number?
Affimed's international securities identification number is: NL0010872420 What is Affimed's CUSIP number?
Affimed's Committee on Uniform Securities Identification Procedures number is: N01045108
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question